Hepatic Oncology Q4 Unclaimed
Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts It has an SJR impact factor of 0,155.
Type: Journal
Type of Copyright: CC BY-NC-ND
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -
1274 €
Inmediate OA- €
Embargoed OA- €
Non OAMetrics
0,155
SJR Impact factor3
H Index4
Total Docs (Last Year)2
Total Docs (3 years)120
Total Refs1
Total Cites (3 years)2
Citable Docs (3 years)0
Cites/Doc (2 years)30.0
Ref/DocOther journals with similar parameters
Experimental Oncology Q4
Journal of Biological Regulators and Homeostatic Agents Q4
Chinese Journal of Oncology Q4
Middle East Journal of Cancer Q4
Acta Haematologica Polonica Q4
Compare this journals
Aims and Scope
Best articles by citations
Molecular classification of hepatocellular carcinoma: potential therapeutic implications
Mechanisms of doxorubicin resistance in hepatocellular carcinoma
Biomarker development for hepatocellular carcinoma early detection: current and future perspectives
Biphenotypic (hepatobiliary) primary liver carcinomas: the work in progress
STAT3 in hepatocellular carcinoma: new perspectives
Dysregulated fatty acid metabolism in hepatocellular carcinoma
RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma
Hepatocellular carcinoma treatment: hurdles, advances and prospects
Systemic treatments for hepatocellular carcinoma: challenges and future perspectives
The biological and clinical challenge of liver cancer heterogeneity
Malignant transformation of hepatocellular adenoma
Locoregional therapies in cholangiocarcinoma
Molecular classification of hepatocellular adenomas: impact on clinical practice
The role of the innate immune system in the development and treatment of hepatocellular carcinoma
Liver cancer oncogenomics: opportunities and dilemmas for clinical applications
Radiologic criteria of response to systemic treatments for hepatocellular carcinoma
A perspective on molecular therapy in cholangiocarcinoma: present status and future directions
The role of AEG-1 in the development of liver cancer
Targeting glucose metabolism in cancer: a new class of agents for loco-regional and systemic therapy of liver cancer and beyond?
How Rap and its GEFs control liver physiology and cancer development. C3G alterations in human hepatocarcinoma
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
JAK/STAT signaling in hepatocellular carcinoma
The impact of antiviral therapy on hepatocellular carcinoma epidemiology
Apoptosis in liver carcinogenesis and chemotherapy
Comments